Want to see KVUE full AI Analyst Report?
Top Page
Kenvue, Inc.
(NYSE:KVUE)
Select Model
Select Model
Rating:70Outperform
Price Target:
$21.50
▲(11.23% Upside)
Action:Upgraded
Date:10/30/26
KVUE scores 70 driven primarily by solid financial performance—strong margins and robust free cash flow—tempered by moderate leverage and historical earnings/cash-flow variability. Technicals add support via an uptrend above key moving averages, while valuation is balanced: a mid-20s P/E offsets a strong ~5.3% dividend yield.
Positive Factors
Sustained sales growth and execution
Four consecutive quarters of net and organic sales growth indicate improving execution and product demand across the portfolio. Combined with margin expansion and strong cash generation, this supports a more durable recovery in operating performance over the next several quarters.
Negative Factors
Meaningful leverage limits flexibility
Although the capital structure is described as manageable, debt remains meaningful relative to equity and can constrain financial flexibility if operating conditions weaken. Leverage may also limit the capacity to fund growth initiatives or absorb weaker cash generation without adjusting capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained sales growth and execution
Four consecutive quarters of net and organic sales growth indicate improving execution and product demand across the portfolio. Combined with margin expansion and strong cash generation, this supports a more durable recovery in operating performance over the next several quarters.
Read all positive factors
Kenvue, Inc. Key Performance Indicators (KPIs)
Any
Adjusted Operating Income by Segment
Shows profitability for each business segment after one‑time items are removed, revealing which parts of Kenvue generate the best margins and which absorb costs; helps investors judge where management should focus investment or cutbacks to drive overall profit growth.
Shows profitability for each business segment after one‑time items are removed, revealing which parts of Kenvue generate the best margins and which absorb costs; helps investors judge where management should focus investment or cutbacks to drive overall profit growth.
Data provided by:
The Fly
The FlyKenvue, Inc. (KVUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.09B
Dividend Yield5.4%
Average Volume (3M)19.10M
Price to Earnings (P/E)21.9
Beta (1Y)0.03
Revenue Growth1.75%
EPS Growth16.81%
CountryUS
Employees21,890
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.88
Shares Outstanding1,920,773,400
10 Day Avg. Volume17,610,109
30 Day Avg. Volume19,101,152
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda12.75
Forecast
1Y Price Target
$19.25Price Target Upside-0.41% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)1.18
Revenue Forecast (FY)$15.61B
Kenvue, Inc. Business Overview & Revenue Model
Company Description
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse r...
Kenvue, Inc. Earnings Call Summary
Earnings Call Date:Jul 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Feb 11, 2027
Earnings Call Sentiment Neutral
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.Positive Updates
Strong Market Share in Self Care
In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
Negative Updates
Disappointing Q2 Financial Performance
Organic sales declined 4.2% year-over-year, which was below expectations. Adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS fell to $0.29 from $0.32.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Market Share in Self Care
In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
Read all positive updates
Company Guidance
During Kenvue's Second Quarter 2025 Earnings Conference Call, the company revised its guidance for fiscal 2025, projecting organic sales to decline in the low single digits with a roughly neutral impact from currency fluctuations. The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which productivity initiatives may not fully offset. Consequently, adjusted diluted EPS is anticipated to range between $1 to $1.05, considering a low single-digit drag from currency. The company highlighted a challenging second quarter, with organic sales declining by 4.2% and adjusted operating margin decreasing by 10 basis points to 22.7%, leading to an adjusted diluted EPS of $0.29. Despite these results, Kenvue remains committed to enhancing operational rigor, improving execution, and strategically reviewing alternatives to unlock shareholder value.Kenvue, Inc. Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
64
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.53B | 15.12B | 15.46B | 15.44B | 14.95B | 15.05B |
| Gross Profit | 9.05B | 8.79B | 8.96B | 8.64B | 8.29B | 8.42B |
| EBITDA | 3.26B | 2.94B | 2.47B | 3.17B | 3.28B | 3.66B |
| Net Income | 1.69B | 1.47B | 1.03B | 1.66B | 2.06B | 2.08B |
Balance Sheet | ||||||
| Total Assets | 26.67B | 27.08B | 25.60B | 27.85B | 27.32B | 27.93B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.06B | 1.07B | 1.38B | 1.23B | 740.00M |
| Total Debt | 8.34B | 8.52B | 8.72B | 8.43B | 9.05B | 129.00M |
| Total Liabilities | 16.51B | 16.31B | 15.93B | 16.64B | 7.35B | 7.53B |
| Stockholders Equity | 10.16B | 10.77B | 9.67B | 11.21B | 19.97B | 20.40B |
Cash Flow | ||||||
| Free Cash Flow | 2.54B | 1.72B | 1.33B | 2.70B | 2.15B | 39.00M |
| Operating Cash Flow | 2.73B | 2.20B | 1.77B | 3.17B | 2.52B | 334.00M |
| Investing Cash Flow | -399.00M | -436.00M | -425.00M | -488.00M | -390.00M | -171.00M |
| Financing Cash Flow | -2.43B | -1.84B | -1.56B | -2.53B | -1.58B | 0.00 |
Kenvue, Inc. Technical Analysis
Positive
19.33
Price Trends
18.32
Positive
18.46
Positive
17.77
Positive
Market Momentum
0.42
Negative
60.49
Neutral
53.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KVUE, the sentiment is Positive. The current price of 19.33 is above the 20-day moving average (MA) of 18.64, above the 50-day MA of 18.32, and above the 200-day MA of 17.77, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 60.49 is Neutral, neither overbought nor oversold. The STOCH value of 53.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KVUE.
Kenvue, Inc. Risk Analysis
Kenvue, Inc. disclosed 144 risk factors in its most recent earnings report. Kenvue, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kenvue, Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $374.48B | 23.94 | 29.55% | 2.68% | 3.52% | -3.74% | |
70 Outperform | $37.09B | 21.94 | 16.06% | 5.40% | 1.75% | 16.81% | |
70 Outperform | $140.57B | 13.75 | 58.26% | 3.41% | -17.45% | 8.84% | |
67 Neutral | $35.90B | 18.36 | 122.57% | 4.72% | -12.19% | -19.22% | |
65 Neutral | $75.96B | 37.02 | 1135.82% | 2.21% | 5.24% | -29.04% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
57 Neutral | $39.58B | 214.18 | 4.63% | 1.28% | 5.51% | ― |
* Consumer Defensive Sector Average
KVUE
Kenvue, Inc.
19.31
5.76
42.52%
CL
Colgate-Palmolive
95.29
20.05
26.64%
EL
The Estée Lauder Companies
109.23
13.90
14.58%
KMB
Kimberly Clark
107.94
-5.94
-5.22%
PG
Procter & Gamble
161.57
15.44
10.57%
UL
Unilever
65.26
2.93
4.70%
Kenvue, Inc. Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Kenvue Amends Senior Notes Ahead Kimberly-Clark Acquisition
Positive
Oct 13, 2026
On October 9, 2026, Kenvue entered into a Third Supplemental Indenture to amend the terms governing several series of its outstanding senior notes, in coordination with Kimberly-Clark’s offers to exchange up to $7 billion of these notes for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.